Vienna - Delayed Quote EUR

argenx SE (ARGX.VI)

504.60
+6.40
+(1.28%)
At close: June 13 at 3:30:39 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,579,913
2,190,231
1,226,316
410,746
497,277
Cost of Revenue
264,916
227,289
117,835
29,431
0
Gross Profit
2,314,997
1,962,942
1,108,481
381,315
497,277
Operating Expense
2,099,965
1,980,786
1,529,119
1,105,234
857,176
Operating Income
215,032
-17,844
-420,638
-723,919
-359,899
Net Non Operating Interest Income Expense
133,876
136,276
92,058
22,548
2,393
Other Income Expense
12,983
-33,252
24,084
-27,942
-42,239
Pretax Income
361,891
85,180
-304,496
-729,314
-399,743
Tax Provision
-702,215
-747,860
-9,443
-19,720
8,522
Net Income Common Stockholders
1,064,106
833,040
-295,053
-709,594
-408,265
Diluted NI Available to Com Stockholders
1,064,106
833,040
-295,053
-709,594
-408,265
Basic EPS
17.74
--
-5.16
-13.05
-7.99
Diluted EPS
16.40
--
-5.16
-13.05
-7.99
Basic Average Shares
60,273.92
--
57,169.25
54,381.37
51,075.83
Diluted Average Shares
66,766.39
--
57,169.25
54,381.37
51,075.83
Total Operating Income as Reported
210,707
-21,654
-425,049
-720,341
-348,746
Rent Expense Supplemental
--
20,888
11,264
9,627
--
Total Expenses
2,364,881
2,208,075
1,646,954
1,134,665
857,176
Net Income from Continuing & Discontinued Operation
1,064,106
833,040
-295,053
-709,594
-408,265
Normalized Income
1,048,249.50
852,246
-322,664.32
-683,066.22
-376,585.75
Interest Income
136,963
138,740
92,962
24,741
3,489
Interest Expense
3,087
2,464
904
2,193
1,096
Net Interest Income
133,876
136,276
92,058
22,548
2,393
EBIT
364,978
87,644
-303,592
-727,121
-398,647
EBITDA
364,978
105,171
-192,285
-622,779
-392,780
Reconciled Cost of Revenue
264,916
212,911
8,894
29,431
0
Reconciled Depreciation
--
17,527
111,307
104,342
5,867
Net Income from Continuing Operation Net Minority Interest
1,064,106
833,040
-295,053
-709,594
-408,265
Total Unusual Items Excluding Goodwill
21,142
-25,608
28,495
-27,265
-42,239
Total Unusual Items
21,142
-25,608
28,495
-27,265
-42,239
Normalized EBITDA
343,836
130,779
-220,780
-595,514
-350,541
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
5,285.50
-6,402
883.68
-737.22
-10,559.75
12/31/2021 - 9/18/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1RV.F Rhythm Pharmaceuticals, Inc.
53.50
-4.46%
 
UNC.F UCB SA
160.85
-1.44%
 
UCB.BR UCB SA
163.45
-0.06%
 
ALNY Alnylam Pharmaceuticals, Inc.
307.99
+1.09%
 
EXEL Exelixis, Inc.
41.59
-0.45%
 
ADMA ADMA Biologics, Inc.
20.81
-3.66%
 
LYRA Lyra Therapeutics, Inc.
11.34
-4.30%
 
RXRX Recursion Pharmaceuticals, Inc.
4.9200
-4.84%